Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
tocilizumab (RoActemra®)
Reference No. 1851
Publication date:
08/05/2014
Last review date:
17/02/2017
Appraisal information
tocilizumab (RoActemra®) 20 mg/ml concentrate for solution for infusion
Company:
Roche Products Ltd
BNF category:
Musculoskeletal and joint diseases
NMG meeting date:
22/01/2014
AWMSG meeting date:
19/02/2014
Submission Type:
Limited Submission
Status:
Superseded
Advice No:
0514
Ratification by Welsh Government:
07/05/2014
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Tocilizumab (RoActemra®) is recommended as an option for use within NHS Wales in combination with methotrexate (MTX) for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
tocilizumab (RoActemra) 1851 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
tocilizumab (RoActemra) 1851 ASAR
Clinical Expert (CE) Summary
Download
tocilizumab (RoActemra) 1851 CE summary